Floatz Rating
CCC51/100
Confidence
Indicative
Sponsor
Wenjun Cheng
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04807166CT.gov Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ovarian Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Catequentinib (this asset) | Wenjun Cheng | P2 | CCC · 51 |
| Adriamycin | GlaxoSmithKline | P4 | BBB |
| Carboplatin | Eli Lilly and Company | P3 | BB |
| Pazopanib | The Christie NHS Foundation Trust | P2 | BB |
| Canfosfamide | Telik | P3 | BB |
| Docetaxel | Merck Sharp & Dohme LLC | P2 | BB |
| Niraparib | GlaxoSmithKline | P4 | BB |
| Nogitecan | GlaxoSmithKline | P3 | B |
| Trabectedin | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | P3 | B |
+42 more in the Ovarian Neoplasm cohort
Other indications for Catequentinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Refractory Malignant Neoplasm | — | P3 | BB · 70 |
| Non-Small Cell Squamous Lung Carcinoma | — | P3 | BB · 66 |
| Kidney Cancer | — | P3 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Catequentinib in Ovarian Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/catequentinib-ovarian-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →